
Just two acquisitions in the first quarter, that of Intra-Cellular Therapies and IDRx, crossed the $1 billion mark, a notable decrease from the six seen during the same period last year.

Just two acquisitions in the first quarter, that of Intra-Cellular Therapies and IDRx, crossed the $1 billion mark, a notable decrease from the six seen during the same period last year.
Warren Expands Its Structural Forensics Practice with Claire Benedict, P.E. July 15, 2026 4:19 pm…
California Walnut كما أظهر بحثٌ جديد أن تناول الجوز في وجبة الإفطار يمكن أن يحسّن…
Arab Newswire - Press release distribution to media in MENA/GCC Regions Newswire expands reach with…
Results presented at the European Society for Medical Oncology meeting could help separate Roche’s medicine from similar hormone-degrading drugs for…
News Antheia and TAPI have formed a strategic partnership to accelerate global commercialization of Antheia’s biosynthetic manufacturing platform for key…
IL2RG protein, encoded by tL2RG complementary DNA. (https://commons.wikimedia.org/wiki/File:Protein_IL2RG_PDB_2b5i.png) As reported in the 18 April issue of the New England Journal…
Tokyo-based Elix (founded 2016) has launched Elix Discovery, an AI drug discovery platform powered by federated learning models trained on…
Sign in to your account